Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
20 Mar 2024
Historique:
received: 05 12 2023
revised: 08 03 2024
accepted: 19 03 2024
medline: 20 3 2024
pubmed: 20 3 2024
entrez: 20 3 2024
Statut: aheadofprint

Résumé

Pemphigus vulgaris is a rare autoimmune bullous disease characterized by blistering of the skin and mucosa owing to the presence of autoantibodies against the desmosome proteins desmoglein 3 and occasionally in conjunction with desmoglein 1. Fundamental research into the pathogenesis of PV has revolutionized its treatment and outcome with rituximab, a B-cell-depleting therapy. The critical contribution of B cells to the pathogenesis of pemphigus is well accepted. However, the exact pathomechanism, mechanisms of onset, disease course, and relapse remain unclear. In this narrative review, we provide an overview of the fundamental research progress that has unfolded over the past centuries to give rise to current and emerging therapies. Furthermore, we summarized the multifaceted roles of B cells in pemphigus vulgaris, including their development, maturation, and antibody activity. Finally, we explored how these various aspects of B-cell function contribute to disease pathogenesis and pave the way for innovative therapeutic interventions.

Identifiants

pubmed: 38504438
pii: 7632162
doi: 10.1093/bjd/ljae107
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.

Auteurs

Anne-Lise Strandmoe (AL)

Department of Medical Biology and Pathology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Department of Dermatology, University of Groningen, University Medical Centre Groningen, Centre for Blistering Diseases, Groningen, the Netherlands.

Jeroen Bremer (J)

Department of Dermatology, University of Groningen, University Medical Centre Groningen, Centre for Blistering Diseases, Groningen, the Netherlands.

Gilles F H Diercks (GFH)

Department of Medical Biology and Pathology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Department of Dermatology, University of Groningen, University Medical Centre Groningen, Centre for Blistering Diseases, Groningen, the Netherlands.

Antoni Gostyński (A)

Department of Dermatology, University of Groningen, University Medical Centre Groningen, Centre for Blistering Diseases, Groningen, the Netherlands.
Department of Dermatology, Maastricht University Medical Centre, Maastricht, the Netherlands.

Emanuele Ammatuna (E)

Department of Haematology-Oncology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

Hendri H Pas (HH)

Department of Dermatology, University of Groningen, University Medical Centre Groningen, Centre for Blistering Diseases, Groningen, the Netherlands.

Marjan Wouthuyzen-Bakker (M)

Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

Gerwin A Huls (GA)

Department of Haematology-Oncology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

Peter Heeringa (P)

Department of Medical Biology and Pathology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

Jon D Laman (JD)

Department of Medical Biology and Pathology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

Barbara Horváth (B)

Department of Dermatology, University of Groningen, University Medical Centre Groningen, Centre for Blistering Diseases, Groningen, the Netherlands.

Classifications MeSH